- Home
- ALLO vs LEO Comparison
ALLO vs LEO Comparison
Compare ALLO & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- LEO
- Stock Information
- Founded
- ALLO 2017
- LEO 1987
- Country
- ALLO United States
- LEO United States
- Employees
- ALLO N/A
- LEO N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- LEO Trusts Except Educational Religious and Charitable
- Sector
- ALLO Health Care
- LEO Finance
- Exchange
- ALLO Nasdaq
- LEO Nasdaq
- Market Cap
- ALLO 431.9M
- LEO 394.9M
- IPO Year
- ALLO 2018
- LEO N/A
- Fundamental
- Price
- ALLO $2.07
- LEO $6.19
- Analyst Decision
- ALLO Buy
- LEO
- Analyst Count
- ALLO 12
- LEO 0
- Target Price
- ALLO $10.06
- LEO N/A
- AVG Volume (30 Days)
- ALLO 2.5M
- LEO 200.2K
- Earning Date
- ALLO 11-07-2024
- LEO 01-01-0001
- Dividend Yield
- ALLO N/A
- LEO 4.01%
- EPS Growth
- ALLO N/A
- LEO N/A
- EPS
- ALLO N/A
- LEO 0.04
- Revenue
- ALLO $43,000.00
- LEO N/A
- Revenue This Year
- ALLO N/A
- LEO N/A
- Revenue Next Year
- ALLO N/A
- LEO N/A
- P/E Ratio
- ALLO N/A
- LEO $152.00
- Revenue Growth
- ALLO 26.47
- LEO N/A
- 52 Week Low
- ALLO $1.83
- LEO $4.98
- 52 Week High
- ALLO $5.78
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- ALLO 41.06
- LEO 34.47
- Support Level
- ALLO $1.83
- LEO $6.34
- Resistance Level
- ALLO $2.09
- LEO $6.47
- Average True Range (ATR)
- ALLO 0.14
- LEO 0.07
- MACD
- ALLO -0.01
- LEO -0.02
- Stochastic Oscillator
- ALLO 30.38
- LEO 3.33
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others.